Digoxin

For research use only.

Catalog No.S4290

6 publications

Digoxin   Chemical Structure

CAS No. 20830-75-5

Digoxin is a classical Na,K-ATPase inhibitor, with selectivity for the α2β3 isoform over the common α1β1 isoform, used in the treatment of atrial fibrillation and heart failure.

Size Price Stock Quantity  
USD 97 In stock
USD 197 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Digoxin has been cited by 6 publications

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Digoxin is a classical Na,K-ATPase inhibitor, with selectivity for the α2β3 isoform over the common α1β1 isoform, used in the treatment of atrial fibrillation and heart failure.
Targets
Na,K-ATPase α2β3 [1]
()
Na,K-ATPase α2β1 [1]
()
Na,K-ATPase α1β1 [1]
()
42.8 nM(Ki) 58.7 nM(Ki) 268 nM(Ki)
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
rat hepatocytes MXzGeY5kfGmxbjDhd5NigQ>? MlfUSJJ2\yC3cIThb4UhcW5icnH0JIhmeGG2b3P5eIV{NCCNbU2wMlE5KM7:TR?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl{Nk[xPUc,OjB7Mk[2NVk9N2F-
human hepatocytes MVLGeY5kfGmxbjDhd5NigQ>? MYqwMlA2KHSxIEGwJJVO NWDhXZV[THK3ZzD1dJRic2ViaX6gd4Fv\HerY3itZ5VtfHW{ZXSgbJVu[W5iaHXwZZRw[3m2ZYOgZZQhOC5yNTD0c{AyOCC3TTDheEA{PyCmZXfDJIJ6KE2rY3jh[Yxqey2PZX70[Y4hc2mwZYTpZ5Mwe2OrboTpcIxifGmxbjDzdIVkfHKxc3PvdJktKEuvPUKuN|kh|ryP MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl{Nk[xPUc,OjB7Mk[2NVk9N2F-
LLC-PK1 NYPDelk{TnWwY4Tpc44h[XO|YYm= MkjFWHBgXFKDTmPQU3JVTVJ8IHnubIljcXSrb36gc4YhTTJzN3LleIFIKHWydHHr[UBqdiCRYYTwNk1mgHC{ZYPzbY5oKEyOQz3QT|Eh[2WubIOsJGtqRTBwMEO3{txO M4H1d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNEC4OVU4Lz5zMUSwPFU2PzxxYU6=
High Five (BTI-TN5B1-4) M{jwXGZ2dmO2aX;uJIF{e2G7 MVPUVH9VWkGQU2DPVnRGWjpiQWTQJIh6\HKxbInzbZMhcW5ibXXtZpJidmViZoLhZ5Rqd25iZoLvcUBJcWeqIF\peoUhMEKWST3UUlVDOS12KTDj[YxteyxiS329NlUvQc7:TR?= NES4dlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUe4OVY5PCd-MUG3PFU3QDR:L3G+
LLC-PK1 M{n2Z2Z2dmO2aX;uJIF{e2G7 M2G5N3RRZ1SUQV7TVG9TXEWUOjDpcohq[mm2aX;uJI9nKFSjdYLvZ4hwdGG2ZTD1dJRic2ViaX6gU4F1eDJvZYjwdoV{e2mwZzDMUGMuWEtzIHPlcIx{NCCNaU2wMlU5|ryP Mmn6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF5OUK2PVQoRjFzN{myOlk1RC:jPh?=
LLC-PK1 MWnGeY5kfGmxbjDhd5NigQ>? MWLUVH9VWkGQU2DPVnRGWjpidYD0ZYtmKGmwIF;heJAzNWW6cILld5NqdmdiTFzDMXBMOSClZXzsd{whU21;MT6wO:69VQ>? M{HGc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzN{myOlk1Lz5zMUe5NlY6PDxxYU6=
LLC-PK1 MnXESpVv[3Srb36gZZN{[Xl? M1fqPHRRZ1SUQV7TVG9TXEWUOjD1dJRic2ViaX6gU4F1eDJvZYjwdoV{e2mwZzDMUGMuWEtzIHPlcIx{NCCNbU2wMlI4Qc7:TR?= NFGyXIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUi4N|Y1OSd-MUG4PFM3PDF:L3G+
MDCK NUnr[nhITnWwY4Tpc44h[XO|YYm= NXX6Nms4XFChVGLBUnNRV1KWRWK6JINmdGxiYXPjeY12dGG2aX;uJIlvKE:DVGC0R|Eu\XiycnXzd4lv\yCPRFPLJINmdGy|LDDLcV04NjkQvF2= NF;id3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEm5N|YxPCd-MUS5PVM3ODR:L3G+
MDCK MUTGeY5kfGmxbjDhd5NigQ>? NWq5RpZMXFChVGLBUnNRV1KWRWK6JINmdGxiYXPjeY12dGG2aX;uJIlvKE:DVGC0R|Eu\XiycnXzd4lv\yCPRFPLJINmdGy|LDDLcV05|ryP NIG0Olk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEm5N|YxPCd-MUS5PVM3ODR:L3G+
TK10 NYf5NYlKS3m2b4TvfIlkcXS7IHHzd4F6 MnS4OFghcHK| NYHRToN{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXEtzMDDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvODF2Nt88US=> NYfOc2VmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[zNFk{OTVpPkG2N|A6OzF3PD;hQi=>
MCF7 NHnHS2dEgXSxdH;4bYNqfHliYYPzZZk> NFrQbYc1QCCqcoO= MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD6wNlQy|ryP NUTiSnJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[zNFk{OTVpPkG2N|A6OzF3PD;hQi=>
K562 NHfSbI1EgXSxdH;4bYNqfHliYYPzZZk> NYjzc3lRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCkeTDYWHQh[XO|YYmsJGlEPTB;MD6wNlgz|ryP NGXkU2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkOwPVMyPSd-MU[zNFk{OTV:L3G+
UACC62 M1\FfmN6fG:2b4jpZ4l1gSCjc4PhfS=> MXW0PEBpenN? NWDZc5VnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXUGFQ{[yJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:OC5yMkm1{txO NELWR|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkOwPVMyPSd-MU[zNFk{OTV:L3G+
HeLa MlLnR5l1d3SxeHnjbZR6KGG|c3H5 NYnOXG4{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKESQQTDy[ZBtcWOjdHnvckBjgSCrbXHnbY5oKGGwYXz5d4l{ MnnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyNk[wOVUoRjF6ME[2NFU2RC:jPh?=
HeLa NEO0eoFHfW6ldHnvckBie3OjeR?= NIm1O3pKdmirYnn0bY9vKG:oIH3peI9{cXNiaX6gbJVu[W5iSHXMZUBk\WyuczDifUBqdWGpaX7nJIFv[Wy7c3nz NID4RmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC2OlA2PSd-MUiwOlYxPTV:L3G+
colon cancer MX3DfZRwfG:6aXPpeJkh[XO|YYm= M{j0WlczKGi{cx?= NUjP[2RWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{KGGodHXyJFczKGi{czDifUBHVUODIH3leIhw\CxiSVO1NF0xNjIQvF2= M{TqTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEm0O|M{Lz5zOUi5OFc{OzxxYU6=
CC20 M1jZdGN6fG:2b4jpZ4l1gSCjc4PhfS=> M3rzblczKGi{cx?= NGX4WnVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBESzJyIHPlcIx{KGGodHXyJFczKGi{czDifUBHVUODIH3leIhw\CxiSVO1NF0xNjJ2zszN Mn61QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OUS3N|MoRjF7OEm0O|M{RC:jPh?=
HCT116 NGDOeYZEgXSxdH;4bYNqfHliYYPzZZk> M4jnVFczKGi{cx?= M{jzUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhTk2FQTDt[ZRpd2RuIFnDOVA:OC5{N988US=> MmG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OUS3N|MoRjF7OEm0O|M{RC:jPh?=
HT-29 NHrDZWVEgXSxdH;4bYNqfHliYYPzZZk> MlrJO|IhcHK| M13HbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KGGodHXyJFczKGi{czDifUBHVUODIH3leIhw\CxiSVO1NF0yNjUQvF2= NUHSbJhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4PVQ4OzNpPkG5PFk1PzN|PD;hQi=>
Hs578Bst NIfrZZFEgXSxdH;4bYNqfHliYYPzZZk> NEKySG44OiCqcoO= NInESHpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJezV5OFLzeEBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OD1yLkC0{txO NYTPTnZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVYyPjhpPkKyN|E3OTZ6PD;hQi=>
Hs578T NVnJ[2hES3m2b4TvfIlkcXS7IHHzd4F6 MkDaO|IhcHK| M4jUfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGh{PTd6VDDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiSVO1NF0xNjJ3Md88US=> M3W5VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{G2NVY5Lz5{MkOxOlE3QDxxYU6=
T47D Ml;JR5l1d3SxeHnjbZR6KGG|c3H5 NHHF[4Y4OiCqcoO= M363NmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHQ1P0RiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUC9NE43Ps7:TR?= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNzNkG2PEc,OjJ|MU[xOlg9N2F-
SK-BR-3 M3e1emN6fG:2b4jpZ4l1gSCjc4PhfS=> M1nnRVczKGi{cx?= NFHzUWJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2EUj2zJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR|UxRTFwMElOwG0> MkHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|MU[xOlgoRjJ{M{G2NVY5RC:jPh?=
MCF7 NXTLSGRqS3m2b4TvfIlkcXS7IHHzd4F6 NHK2S3U4OiCqcoO= NEfadlJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCLQ{WwQVQvP87:TR?= M4X1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{G2NVY5Lz5{MkOxOlE3QDxxYU6=
Hs578Bst MmjpR5l1d3SxeHnjbZR6KGG|c3H5 MnfwOFAhfU1? NVPDS5ZRPzJiaILz M1H0OGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGh{PTd6QoP0JINmdGy|IHH0JFQxKHWPIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7IILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;sMEBKSzVyPUS3MlfPxE1? NV;uSXBYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNVYyPjhpPkKyN|E3OTZ6PD;hQi=>
CHO NUfCWIdFTnWwY4Tpc44h[XO|YYm= NUHLS3lReEmFNUCgeoFtfWW|IH\vdkB{d2SrdX2g[ox2d3Knc3PlbY4hMDFyIIXNLUB2eHSja3WgbY4hV0GWUEHCNU11emGwc3\lZ5Rm\CCFSF:gZ4VtdHNuIFnDOVA:Oy5{M{W5OO69VQ>? NUnNbXdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1O|E1OTVpPkKzOVcyPDF3PD;hQi=>
CHO NFPEWHRHfW6ldHnvckBie3OjeR?= MUHwTWM2OCC4YXz1[ZMh\m:{IIPv[Il2dSCobIXvdoV{[2WrbjCoNVAhfU1rIIXweIFs\SCrbjDPRXRROUJ|LYTyZY5{\mWldHXkJGNJVyClZXzsd{whUUN3ME2xN{4yQDJ4zszN MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5MUSxOUc,OjN3N{G0NVU9N2F-
Hs683 NWnNNJdES3m2b4TvfIlkcXS7IHHzd4F6 MVSzJIRigXN? MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDId|Y5OyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFTPxE1? NG\XRYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewOlAxPSd-MkO3NFYxODV:L3G+
A549 Mn;NR5l1d3SxeHnjbZR6KGG|c3H5 MWezJIRigXN? MnvCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFXPxE1? M4HYVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{C2NFA2Lz5{M{ewOlAxPTxxYU6=
PC3 NXjYOFhiS3m2b4TvfIlkcXS7IHHzd4F6 Mnv2N{Bl[Xm| NXXTS4NxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9NE4xPzYQvF2= NGLzR|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewOlAxPSd-MkO3NFYxODV:L3G+
U373 NXXXNZVKS3m2b4TvfIlkcXS7IHHzd4F6 NYf5NIFSOyCmYYnz MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVN|c{KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6xOFbPxE1? NH7qPIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewOlAxPSd-MkO3NFYxODV:L3G+
SK-MEL-28 MYXDfZRwfG:6aXPpeJkh[XO|YYm= M4X2OlMh\GG7cx?= M{DQN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU2HTD2yPEBk\WyuczDh[pRmeiB|IHThfZMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMk[2{txO M{\WdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{C2NFA2Lz5{M{ewOlAxPTxxYU6=
MCF7 NXjDTZF[S3m2b4TvfIlkcXS7IHHzd4F6 MkDvN{Bl[Xm| MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;MD60NlbPxE1? NWjub5F7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFYxODVpPkKzO|A3ODB3PD;hQi=>
Drosophila Schneider cells NFnoWWVHfW6ldHnvckBie3OjeR?= NH\iXItCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IITyZY5{[WO2aY\heIlwdiCmb33hbY4hd2ZiUl;S[4FudWG2IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGRzd3OxcHjpcIEhW2OqbnXp[IVzKGOnbHzzJINwNWW6cILld5NqdmdiR3HsOE1FVkFiYnnu[Ilv\yCmb33hbY4tKEmFNUC9Nu69VQ>? NFrleWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0NFQ5Pid-MkSwOFA1QDZ:L3G+
Drosophila Schneider cells NXLnT|NHTnWwY4Tpc44h[XO|YYm= NVq1eJB3SW62YXfvcol{fCCjY4Tpeol1gSCjdDD0doFve2GldHn2ZZRqd25iZH;tZYlvKG:oIGLPVodidW2jdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBFem:|b4DobYxiKFOlaH7lbYRmeiClZXzsd{Bkdy2neIDy[ZN{cW6pIFfhcFQuTE6DIHLpcoRqdmdiZH;tZYlvNCCLQ{WwQVLPxE1? M1nOWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MESwOFg3Lz5{NEC0NFQ5PjxxYU6=
RKO-AS45-1 M3njdmN6fG:2b4jpZ4l1gSCjc4PhfS=> M3yzeVQ5KGi{cx?= M2rBOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJMVy2DU{S1MVEh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkSy{txO NYrvT|JyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlI4PzJpPkK2NVIzPzd{PD;hQi=>
HeLa MYLDfZRwfG:6aXPpeJkh[XO|YYm= M1HKV|Q5KGi{cx?= NXvXUpVwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVIvOs7:TR?= NILDXoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyNlc4Oid-Mk[xNlI4PzJ:L3G+
HeLa MojoSpVv[3Srb36gZZN{[Xl? NUS1b486OTVyIH7N MoK3NlQhcHK| NVnzOWh1UW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{Mke3Nkc,OjZzMkK3O|I9N2F-
HeLa M2XkemZ2dmO2aX;uJIF{e2G7 NWS5RVhwOTVyIH7N MkjPNlQhcHK| NI\jcVhKdmirYnn0bY9vKG:oIF7hLEsqN0tqKzmgRXRR[XOnIHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOTVyIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>? NV\1eXJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlI4PzJpPkK2NVIzPzd{PD;hQi=>
HeLa NYDWZ4FqTnWwY4Tpc44h[XO|YYm= NHSyPJQyPTBibl2= MX2yOEBpenN? M4rOZmlvcGmkaYTpc44hd2ZiTnGoL{kwUyhtKTDBWHBie2ViaX6gbJVu[W5iSHXMZUBk\WyuczDheEAyPTBibl2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4T0bY5o MmD4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkK3O|IoRjJ4MUKyO|czRC:jPh?=
HeLa MoLmSpVv[3Srb36gZZN{[Xl? NHP4d5IyPTBibl2= NX\2XJRsOjRiaILz M1vSXmlvcGmkaYTpc44hd2ZiTnGoL{kwUyhtKTDBWHBie2ViaX6gbJVu[W5iSHXMZUBk\WyuczDheEAyPTBibl2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4T0bY5o M2DnNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUKyO|czLz5{NkGyNlc4OjxxYU6=
HeLa NEPzWppHfW6ldHnvckBie3OjeR?= NI\ke|IyPTBibl2= MUCyOEBpenN? NXvOZ5M6UW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? M4Dk[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUKyO|czLz5{NkGyNlc4OjxxYU6=
HeLa NYTBcXVvTnWwY4Tpc44h[XO|YYm= M{S5T|E2OCCwTR?= MX[yOEBpenN? NVP6[odRUW6qaXLpeIlwdiCxZjDOZUgsMS:NKDupJGFVWGG|ZTDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDF3MDDuUUBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveJRqdmd? MnmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMkK3O|IoRjJ4MUKyO|czRC:jPh?=
HeLa MnLESpVv[3Srb36gZZN{[Xl? NXHVXI1SOTVyIH7N MkeyNlQhcHK| NFTvZoFKdmirYnn0bY9vKG:oIF7hLEsqN0tqKzmgRXRR[XOnIHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOTVyIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{Mke3Nkc,OjZzMkK3O|I9N2F-
HeLa MkmzSpVv[3Srb36gZZN{[Xl? M4r6dlE2OCCwTR?= MV6yOEBpenN? MmP1TY5pcWKrdHnvckBw\iCQYTirLU9MMCtrIFHUVIF{\SCrbjDoeY1idiCKZVzhJINmdGy|IHH0JFE2OCCwTTDh[pRmeiB{NDDodpMh[nliaX3teY5w[myxdITpcoc> NXrYb5c5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlI4PzJpPkK2NVIzPzd{PD;hQi=>
Kasumi-1 M1X3U2N6fG:2b4jpZ4l1gSCjc4PhfS=> MnjVOFghcHK| M4X5WGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtie3WvaT2xJINmdGy|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WUzDhd5NigSxiSVO1NF0xNjB7M988US=> M3LHcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUizPFQzLz5{N{m4N|g1OjxxYU6=
MV4-11 M1[zRWN6fG:2b4jpZ4l1gSCjc4PhfS=> Mn7WOFghcHK| M3jiR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1XPC1zMTDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNiYYPzZZktKEmFNUC9NE4yOTIQvF2= NHXzS2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m4N|g1Oid-Mke5PFM5PDJ:L3G+
HT-29 NE\Kco1EgXSxdH;4bYNqfHliYYPzZZk> NXO2fXRUPzJiaILz NF7VSllEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4{QM7:TR?= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl6M{i0Nkc,Ojd7OEO4OFI9N2F-
H1299 MoSzR5l1d3SxeHnjbZR6KGG|c3H5 NUfMcZF4OjRiaILz NVH5SYgzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDF{OUmgZ4VtdHNiaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvPDcQvF2= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl6M{i0Nkc,Ojd7OEO4OFI9N2F-
CCD-112CoN NUfWc5VnS3m2b4TvfIlkcXS7IHHzd4F6 M1z2c|czKGi{cx?= M3r2Z2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNETC1zMULDc24h[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUC9Nk41|ryP NYXkVlg1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PFM5PDJpPkK3PVg{QDR{PD;hQi=>
DU145 MWDGeY5kfGmxbjDhd5NigQ>? MXe1NEB2VQ>? NIe1SmI2KGi{cx?= NIrSTW9KdmirYnn0bY9vKG:oIF7hL{9MMyCDVGDhd4UheHWvcDDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDpcpRz[WOnbHz1cIFzKGOjbHPpeY0hdGW4ZXygZZQhPTBidV2gcYVie3W{ZXSgZYZ1\XJiNTDodpMh[nliRoXyZU0zN0GPIHT5[UBj[XOnZDDmcJVwemW|Y3XuZ4Uh[XO|YYm= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTF{MEK1NUc,OzFzMkCyOVE9N2F-
DU145 NEe0eWlHfW6ldHnvckBie3OjeR?= NILlXmQ2OCC3TR?= MVu1JIhzew>? NWLZRohVUW6qaXLpeIlwdiCxZjDOZUswUytiQWTQZZNmKHC3bYCgbY4hcHWvYX6gSHUyPDViY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClYXzjbZVuKGyndnXsJIF1KDVyIIXNJI1m[XO3cnXkJIFnfGW{IEWgbJJ{KGK7IF\1doEuOi:DTTDkfYUh[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5 MmjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMkCyOVEoRjNzMUKwNlUyRC:jPh?=
DU145 NYnKPIJQTnWwY4Tpc44h[XO|YYm= NEKyOIY2OCC3TR?= NVnjW5VWPSCqcoO= Mn7OTY5pcWKrdHnvckBw\iCQYTuvT{shSVSSYYPlJJB2dXBiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBk[WylaYXtJIxmfmWuIHH0JFUxKHWPIH3lZZN2emWmIHHmeIVzKDViaILzJIJ6KE[3cnGtNk9CVSCmeXWgZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7 M3juSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUKwNlUyLz5|MUGyNFI2OTxxYU6=
DU145 NWPieIJtTnWwY4Tpc44h[XO|YYm= NXLleFd7PTBidV2= MnjXOUBpenN? M37L[2lvcGmkaYTpc44hd2ZiTnGrM2ssKEGWUHHz[UBxfW2yIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHnueJJi[2WubIXsZZIh[2GuY3n1cUBt\X[nbDDheEA2OCC3TTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCIdYLhMVIwSU1iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?= MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTF{MEK1NUc,OzFzMkCyOVE9N2F-
DU145 M1\POmZ2dmO2aX;uJIF{e2G7 M{f4UlUxKHWP M3vnc|UhcHK| NH7Jd4VKdmirYnn0bY9vKG:oIF7hL{9MMyCDVGDhd4UheHWvcDDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDpcpRz[WOnbHz1cIFzKGOjbHPpeY0hdGW4ZXygZZQhPTBidV2gcYVie3W{ZXSgZYZ1\XJiNTDodpMh[nliRoXyZU0zN0GPIHT5[UBj[XOnZDDmcJVwemW|Y3XuZ4Uh[XO|YYm= M4rnRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUKwNlUyLz5|MUGyNFI2OTxxYU6=
DU145 NWLFSpJlTnWwY4Tpc44h[XO|YYm= NXO0OWtYPTBidV2= M3jOUFUhcHK| MXrJcohq[mm2aX;uJI9nKE6jKz;LL{BCXFCjc3WgdJVueCCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINidGOrdX2gcIV3\WxiYYSgOVAhfU1ibXXhd5Vz\WRiYX\0[ZIhPSCqcoOgZpkhTnW{YT2yM2FOKGS7ZTDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[Xl? MmnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFzMkCyOVEoRjNzMUKwNlUyRC:jPh?=
DU145 NXHnRYRmTnWwY4Tpc44h[XO|YYm= NE\tfHA2OCC3TR?= MYO1JIhzew>? M2PvUGlvcGmkaYTpc44hd2ZiTnGrM2ssKEGWUHHz[UBxfW2yIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHnueJJi[2WubIXsZZIh[2GuY3n1cUBt\X[nbDDheEA2OCC3TTDt[YF{fXKnZDDh[pRmeiB3IHjyd{BjgSCIdYLhMVIwSU1iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeR?= M1HHSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMUKwNlUyLz5|MUGyNFI2OTxxYU6=
DU145 M{nVSGZ2dmO2aX;uJIF{e2G7 M{m4ZVUxKHWP NXXLcnZZPSCqcoO= MYXJcohq[mm2aX;uJI9nKE6jKz;LL{BCXFCjc3WgdJVueCCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCrboTyZYNmdGy3bHHyJINidGOrdX2gcIV3\WxiYYSgOVAhfU1ibXXhd5Vz\WRiYX\0[ZIhPSCqcoOgZpkhTnW{YT2yM2FOKGS7ZTDiZZNm\CCobIXvdoV{[2WwY3WgZZN{[Xl? NIfMXVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUGyNFI2OSd-M{GxNlAzPTF:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Src / Src / p-EGFR / EGFR / p-STAT3 / STAT3 ; 

PubMed: 25955608     


Analysis of phosphorylated and non-phosphorylated Src, EGFR and STAT3 in A549 cells in a dose-dependent manner. The cancer cells treated with or without various concentrations of digoxin (50, 100, 250 and 500 nM) or 100 nM dasatinib for 24 h were analyzed by Western blot. 

p-PI3K / PI3K / p-AKT / AKT / p-MEK / MEK / p-ERK / ERK / p-FAK / FAK / p-SAPK/JNK / p-Paxillin / Paxillin / p-p130Cas / p130Cas ; 

PubMed: 25955608     


Western blotting analyses of phosphorylated and non-phosphorylated PI3K, AKT, MEK1/2, ERK, FAK, SAPK/JNK, paxillin and p130Cas in (a) A549 cell lines after a 24-h treatment with 100, 250 or 500 nM digoxin. The solvent control was 0.1% DMSO; GAPDH was used as an internal control. 

Nrf2; 

PubMed: 30735911     


Digoxin inhibited the Nrf2 signaling in SW1990/Gem and Panc-1/Gem cells. (A–B) Effects of digoxin on the protein level of Nrf2 in SW1990/Gem and Panc-1/Gem cells. (C–D) Effects of digoxin on the protein level of Nrf2 in SW1990/Gem and Panc-1/Gem cells at different time points.

25955608 30735911
Growth inhibition assay
Cell viability; 

PubMed: 25955608     


Five lung cancer cell lines, (a) A549, (b) H3255, (c) H1975, (d) PC9 and (e) PC9/gef, were treated with 6 different doses (0, 0.01, 0.05, 0.1, 1 and 5 μM) of digoxin at different time points (0, 24, 48, 72 and 96 h), and cell viability was measured using the PrestoBlue Cell Viability reagent after treatment. Quantitative data are presented as the mean±SD (n = 3); *p<0.05 compared with solvent control (0.1% DMSO) at the corresponding time point.

25955608

Protocol

Solubility (25°C)

In vitro DMSO 100 mg/mL (128.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+corn oil
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 780.94
Formula

C41H64O14

CAS No. 20830-75-5
Storage powder
in solvent
Synonyms N/A
Smiles CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03559868 Not yet recruiting Drug: Digoxin|Other: Placebo Inflammatory Response Yale University December 20 2020 Phase 1
NCT04457180 Recruiting Drug: Apatinib Mesylate|Drug: Repaglinide|Drug: Bupropion Advanced Solid Tumor Jiangsu HengRui Medicine Co. Ltd. June 25 2020 Phase 1
NCT04322552 Recruiting Drug: Apatinib Mesylate|Drug: Digoxin tablet Advanced Solid Tumor Jiangsu HengRui Medicine Co. Ltd. March 12 2020 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Digoxin | Digoxin supplier | purchase Digoxin | Digoxin cost | Digoxin manufacturer | order Digoxin | Digoxin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID